Innoviva Stock Earnings Estimates Boosted by HC Wainwright

Innoviva, Inc. (NASDAQ:INVA – Free Report) – Research analysts at HC Wainwright lifted their FY2026 EPS estimates for Innoviva in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings per share of $2.37 for the year, up from their previous estimate of $2.30. The consensus estimate for Innoviva’s current full-year earnings is $1.52 per share. HC Wainwright also issued estimates for Innoviva’s Q2 2027 earnings at $0.59 EPS and FY2027 earnings at $2.30 EPS.

Other research analysts have also issued reports about the company. Cantor Fitzgerald reduced their target price on Innoviva from $36.00 to $34.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. Oppenheimer lowered their price target on Innoviva from $35.00 to $34.00 and set an “outperform” rating for the company in a report on Thursday, November 5th. Zacks Research raised Innoviva from a “strong sell” rating to a “hold” rating in a research report on Monday, August 31st. Wall Street Zen lowered Innoviva from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings upgraded Innoviva from a “hold (c+)” rating to a “buy (b)” rating in a report on Monday, November 9th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $39.00.

Get Our Latest Report on INVA

Innoviva Price Performance

INVA opened at $18.49 on Tuesday. The stock has a market cap of $1.31 billion, a P/E ratio of 9.29, a P/E/G ratio of 4.15 and a beta of 0.38. Innoviva has a 12 month low of $18.41 and a 12 month high of $25.15. The company has a quick ratio of 14.58, a current ratio of 15.44 and a debt-to-equity ratio of 0.23. The company has a fifty day simple moving average of $20.64 and a 200 day simple moving average of $21.85.

Innoviva (NASDAQ:INVA – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.52 by ($1.55). Innoviva had a net margin of 44.13% and a return on equity of 22.91%. The firm had revenue of $106.12 million during the quarter, compared to analyst estimates of $115.31 million.

Institutional Investors Weigh In On Innoviva

Several large investors have recently made changes to their positions in the stock. Chase Investment Counsel Corp acquired a new stake in Innoviva in the 2nd quarter valued at $1,589,000. Hsbc Holdings PLC bought a new stake in Innoviva during the 2nd quarter worth about $843,000. Bank of America Corp DE acquired a new position in shares of Innoviva during the 2nd quarter worth about $37,873,000. Baird Financial Group Inc. acquired a new position in shares of Innoviva during the 2nd quarter worth about $6,231,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Innoviva by 1.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,436,427 shares of the biotechnology company’s stock worth $103,366,000 after buying an additional 76,026 shares during the last quarter. Institutional investors own 99.12% of the company’s stock.

Innoviva Company Profile

(Get Free Report)

Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.

Further Reading

Earnings History and Estimates for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.